Thermo Fisher Scientific to Support mRNA-based Vaccine Candidate Production for BioNTech

Tuesday, February 26, 2019 Drug News
Email Print This Page Comment bookmark
Font : A-A+

Agreement ensures consistent supply of nucleotides, enzymes and other critical raw materials for messenger RNA (mRNA) vaccine manufacturing platform

WALTHAM, Mass., Feb. 26, 2019 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, today announced

it has signed a multi-year agreement with Mainz, Germany-based BioNTech focused on supplying critical raw materials for the manufacturing of precise immunotherapy vaccine candidates.

Under the agreement, Thermo Fisher will supply nucleotides, enzymes and other critical raw materials to support BioNTech's messenger RNA (mRNA) manufacturing platform. The four-year, nonexclusive licensing and supply agreement gives BioNTech rights to use Thermo Fisher's technologies as part of its clinical and commercial manufacturing processes.

"Our portfolio of molecular biology products is now enabling development and commercialization of multiple individualized therapies and other advanced medicines and we continue to expand our capabilities to meet increasing demand," said Gianluca Pettiti, president, biosciences, Thermo Fisher Scientific. "We share BioNTech's commitment to deliver life-saving therapies to patients faster, and we look forward to supporting them through clinical trials and post-approval production."

"The relationship with Thermo Fisher Scientific secures our access to customized material essential for the manufacturing and commercialization of our RNA-based product candidates," said Ugur Sahin, M.D., co-founder and CEO of BioNTech. "In addition, as a life science services leader, Thermo Fisher can also deliver reagents at the scale needed to expand our manufacturing capacities."

No other terms from this transaction were disclosed.

About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For more information, please visit www.thermofisher.com.

Media Contact Information: Ron O'Brien Thermo Fisher Scientific 781-622-1242 ron.obrien@thermofisher.com

 

Cision View original content:http://www.prnewswire.com/news-releases/thermo-fisher-scientific-to-support-mrna-based-vaccine-candidate-production-for-biontech-300801628.html

SOURCE Thermo Fisher Scientific



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store